Matching articles for "testosterone"
Issue 1726 · April 14, 2025 Free
In Brief: Label Changes for Testosterone Products

The FDA has required changes in the labels of all testosterone products to reflect new data on their cardiovascular effects. The updated labels will no longer include a boxed warning about an increased risk of…

Med Lett Drugs Ther. 2025 Apr 14; 67(1726):62-3 doi:10.58347/tml.2025.1726d
The FDA has required changes in the labels of all testosterone products to reflect new data on their cardiovascular effects. The updated labels will no longer include a boxed warning about an increased risk of adverse cardiovascular outcomes, but will contain a new warning about an increase in blood pressure.
Issue 1724 · March 17, 2025 Free
In Brief: Azmiro — A Single-Dose Injectable Formulation of Testosterone Cypionate

The FDA has approved Azmiro (Azurity), the first injectable formulation of testosterone cypionate to become available in single-dose vials and prefilled syringes for treatment of males with conditions…

Med Lett Drugs Ther. 2025 Mar 17; 67(1724):44-5 doi:10.58347/tml.2025.1724b
The FDA has approved Azmiro (Azurity), the first injectable formulation of testosterone cypionate to become available in single-dose vials and prefilled syringes for treatment of males with conditions associated with a deficiency or absence of endogenous testosterone. Injectable testosterone cypionate has been available in multidose vials ( Depo-Testosterone , and generics) for many years. Testosterone enanthate (Xyosted) is available in prefilled autoinjectors for use in adult men. No testosterone products are approved for treatment of low testosterone levels due solely to aging. All testosterone products are classified as schedule III controlled substances.
Issue 1662 · October 31, 2022
Two New Oral Testosterone Products for Hypogonadism

The FDA has approved two new oral formulations of testosterone undecanoate — Kyzatrex (Marius) and Tlando (Antares) — for treatment of males with a deficiency of endogenous testosterone due to conditions…

Med Lett Drugs Ther. 2022 Oct 31; 64(1662):172-4
The FDA has approved two new oral formulations of testosterone undecanoate — Kyzatrex (Marius) and Tlando (Antares) — for treatment of males with a deficiency of endogenous testosterone due to conditions such as Klinefelter syndrome, orchiectomy, toxic damage from chemotherapy or alcohol, or pituitary-hypothalamic injury caused by tumors, trauma, or radiation. Jatenzo , another oral testosterone undecanoate formulation, was approved for the same indication in 2019. No testosterone products are approved for treatment of low testosterone levels due solely to aging.
Issue 1567 · March 11, 2019
Xyosted - A Testosterone Auto-Injector for Hypogonadism

The FDA has approved an auto-injector formulation of testosterone enanthate ( Xyosted – Antares Pharma) for once-weekly subcutaneous self-administration in adult males with conditions associated with a…

Med Lett Drugs Ther. 2019 Mar 11; 61(1567):37-8
The FDA has approved an auto-injector formulation of testosterone enanthate ( Xyosted – Antares Pharma) for once-weekly subcutaneous self-administration in adult males with conditions associated with a deficiency or absence of endogenous testosterone. It is the first subcutaneous formulation of testosterone to be approved by the FDA. Xyosted is contraindicated for treatment of low testosterone levels associated with aging.
Issue 1490 · March 14, 2016
Safety of Testosterone Replacement Therapy

Three coordinated double-blind, placebo-controlled clinical trials have evaluated the efficacy of one year of testosterone replacement therapy in improving sexual function, physical function, and vitality in a…

Med Lett Drugs Ther. 2016 Mar 14; 58(1490):33-4
Three coordinated double-blind, placebo-controlled clinical trials have evaluated the efficacy of one year of testosterone replacement therapy in improving sexual function, physical function, and vitality in a total of 790 men ≥65 years old with moderately low serum testosterone concentrations and symptoms suggesting hypoandrogenism. Sexual function improved modestly, and there appeared to be marginal benefits in some areas of physical function and vitality as well. The trials were not designed to evaluate the safety of testosterone replacement therapy.
Issue 1468 · May 11, 2015
Testosterone Nasal Gel (Natesto) for Hypogonadism

The FDA has approved an intranasal gel formulation of testosterone ( Natesto – Trimel/Endo) for replacement therapy in men with hypogonadism. Packaged in a metered-dose pump, Natesto is the first intranasal…

Med Lett Drugs Ther. 2015 May 11; 57(1468):73-4
The FDA has approved an intranasal gel formulation of testosterone ( Natesto – Trimel/Endo) for replacement therapy in men with hypogonadism. Packaged in a metered-dose pump, Natesto is the first intranasal testosterone to become available in the US. Like other testosterone products, it is classified as a schedule III controlled substance. The FDA recently cautioned against using testosterone to treat low testosterone levels solely due to aging because the benefits and safety of such use have not been established, and there is a possible increased risk of myocardial infarction (MI) and stroke.
Issue 1439 · March 31, 2014
A Long-Acting Depot Formulation of Testosterone (Aveed)

The FDA has approved testosterone undecanoate ( Aveed – Endo), an injectable depot formulation, for use in men with hypogonadism who require testosterone replacement therapy.

Med Lett Drugs Ther. 2014 Mar 31; 56(1439):26-8
The FDA has approved testosterone undecanoate ( Aveed – Endo), an injectable depot formulation, for use in men with hypogonadism who require testosterone replacement therapy.
Issue 1437 · March 3, 2014 Free
In Brief: Testosterone and Cardiovascular Risk

Prompted by the recent publication of 2 retrospective studies, the FDA has announced that it is investigating the risk of stroke, heart attack, and death in men taking FDA-approved testosterone products. 1 The…

Med Lett Drugs Ther. 2014 Mar 3; 56(1437):17
Prompted by the recent publication of 2 retrospective studies, the FDA has announced that it is investigating the risk of stroke, heart attack, and death in men taking FDA-approved testosterone products. 1 The first study examined the records of 8709 men with low testosterone levels (<300 ng/dL) who underwent coronary angiography between 2005 and 2011; 1223 of these men started testosterone therapy after a median of 531 days following coronary angiography. Three years after coronary angiography, the Kaplan-Meier estimated cumulative percentages of men who died or had a myocardial infarction (MI) or ischemic stroke were 26% of those treated with testosterone and 20% of those who were not treated with the hormone, a hazard ratio of 1.29 (95% CI 1.04-1.58; P=0.02). 2 The second study compared the rate of nonfatal MI during the 90 days after filling a prescription with the rate in the prior year in 56,000 men given a prescription for testosterone and in 167,000 given a phosphodiesterase type 5 inhibitor (sildenafil [Viagra] or tadalafil [Cialis] ). In the testosterone group as a whole, the post/pre-prescription rate ratio was 1.36, but in men ≥65 years old it was 2.19 and in younger men with a history of heart disease it was 2.90. In men who received a prescription for sildenafil or tadalafil, the rate ratio was 1.08 for all ages, 1.15 for those ≥65 years old, and 1.40 for younger men with a history of heart disease. 3 A recent meta-analysis of randomized, placebo-controlled trials of testosterone therapy also found an increased risk of cardiovascular-related events in men treated with the hormone (odds ratio [OR] 1.54; 95% CI 1.09-2.18); an analysis by funding source found that the risk was greater in trials not funded by the pharmaceutical industry (OR 2.06 vs. 0.89). 4 1. FDA Drug Safety Communication January 31, 2014: FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products. Available at www.fda.gov. Accessed February 24, 2014. 2. R Vigen et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013; 310:1829. 3. WD Finkle et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014; 9:e85805. 4. L Xu et al. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 2013; 11:108. Download complete U.S. English article
Issue 1368 · July 11, 2011
Testosterone Topical Solution (Axiron) for Hypogonadism

The Medical Letter recently reviewed a topical gel formulation of testosterone (Fortesta) for treatment of hypogonadism in men. A topical testosterone replacement product for application to the axilla, Axiron…

Med Lett Drugs Ther. 2011 Jul 11; 53(1368):54-5
The Medical Letter recently reviewed a topical gel formulation of testosterone (Fortesta) for treatment of hypogonadism in men. A topical testosterone replacement product for application to the axilla, Axiron (Lilly) solution, has now become available for the same indication. This site of application presumably minimizes the risk of transferring the drug to a family member or sexual partner.
Issue 1362 · April 18, 2011
A New Testosterone Gel (Fortesta) for Hypogonadism

The FDA has approved Fortesta (Endo), a topical gel, for testosterone replacement therapy in adult males with hypogonadism. It is classified as a Schedule III controlled substance. Table 1 lists some available…

Med Lett Drugs Ther. 2011 Apr 18; 53(1362):29-30
The FDA has approved Fortesta (Endo), a topical gel, for testosterone replacement therapy in adult males with hypogonadism. It is classified as a Schedule III controlled substance. Table 1 lists some available testosterone products, including 2 other gels.
Issue 1353 · December 13, 2010
Drugs for Female Sexual Dysfunction

Sexual complaints related to desire, arousal, orgasm and painful intercourse are common in women. Since the last Medical Letter article on this subject, some new information has become available.

Med Lett Drugs Ther. 2010 Dec 13; 52(1353):100-2
Sexual complaints related to desire, arousal, orgasm and painful intercourse are common in women. Since the last Medical Letter article on this subject, some new information has become available.
Issue 1339 · May 31, 2010
Bioidentical Hormones

In recent years, many women have become concerned about the safety of pharmaceutical replacement hormones for treatment of menopausal symptoms. “Bioidentical” hormone preparations, which are not approved…

Med Lett Drugs Ther. 2010 May 31; 52(1339):43-4
In recent years, many women have become concerned about the safety of pharmaceutical replacement hormones for treatment of menopausal symptoms. “Bioidentical” hormone preparations, which are not approved by the FDA, are heavily promoted in popular books and on TV as alternatives; these are derivatives of soy or plant extracts, chemically modified to be structurally identical to endogenous hormones. Most FDA-approved single-entity hormones are also derivatives of soy or plant extracts and are structurally identical to hormones produced by the ovary.
Issue 1323 · October 19, 2009
Degarelix (Firmagon) for Prostate Cancer

The FDA has approved degarelix ( Firmagon - Ferring), a synthetic decapeptide gonadotropin-releasing hormone (GnRH) receptor antagonist, for rapid medical castration of men with advanced prostate cancer.…

Med Lett Drugs Ther. 2009 Oct 19; 51(1323):82-3
The FDA has approved degarelix ( Firmagon - Ferring), a synthetic decapeptide gonadotropin-releasing hormone (GnRH) receptor antagonist, for rapid medical castration of men with advanced prostate cancer. Abarelix (Plenaxis) , the first GnRH antagonist approved by the FDA, was withdrawn from the US market because of immediate hypersensitivity reactions.
Issue 1289 · June 30, 2008
Finasteride for Prevention of Prostate Cancer

Patients are asking physicians about an article on the front page of the June 15th New York Times, in which some prostate cancer experts were quoted as suggesting that men 55 and older might be well advised to…

Med Lett Drugs Ther. 2008 Jun 30; 50(1289):49-50
Patients are asking physicians about an article on the front page of the June 15th New York Times, in which some prostate cancer experts were quoted as suggesting that men 55 and older might be well advised to take finasteride ( Proscar , and others) to prevent prostate cancer.
Issue 1259 · April 23, 2007
Drugs for Female Sexual Dysfunction

Sexual complaints related to desire, arousal, orgasm and pain are common in women. No drugs are approved by the FDA for any of these indications, but many are used off-label.

Med Lett Drugs Ther. 2007 Apr 23; 49(1259):33-5
Sexual complaints related to desire, arousal, orgasm and pain are common in women. No drugs are approved by the FDA for any of these indications, but many are used off-label.
Issue 1187 · July 19, 2004
Performance-Enhancing Drugs

With the 2004 Olympics only weeks away, performance-enhancing drugs will once again be receiving a great deal of attention. The US Anti-Doping Agency has published a list of drugs banned in Olympic sports (…

Med Lett Drugs Ther. 2004 Jul 19; 46(1187):57-9
With the 2004 Olympics only weeks away, performance-enhancing drugs will once again be receiving a great deal of attention. The US Anti-Doping Agency has published a list of drugs banned in Olympic sports ( www.usantidoping.org ) that includes, at least for some sports, all but 2 of the drugs reviewed here.
Issue 1164 · September 1, 2003
Testim and Striant - Two New Testosterone Products

Two new topical testosterone products, a 1% gel (Testim) and a buccal tablet (Striant), have been approved by the FDA for treatment of hypogonadism in men. This review briefly describes hypogonadism and its…

Med Lett Drugs Ther. 2003 Sep 1; 45(1164):70-2
Two new topical testosterone products, a 1% gel (Testim) and a buccal tablet (Striant), have been approved by the FDA for treatment of hypogonadism in men. This review briefly describes hypogonadism and its causes and lists other available formulations of testosterone. For the new products, information on pharmocokinetics, adverse effects, and dosage and administration is provided, as well as a summary of clinical trial results. A dosage and cost table for topical testosterone products is also included. The conclusion summarizes the safety and effectiveness of the new drugs and discusses the potential risks and benefits of using testosterone replacement therapy in older men.
Issue 1158 · June 8, 2003
Drug Interactions

Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug…

Med Lett Drugs Ther. 2003 Jun 8; 45(1158):46-8
Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.
Issue 1056 · July 2, 1999
Drug Interactions

Reports of adverse interactions between drugs continue to accumulate. Recently, the FDA has expanded the recommendations on drug interactions found in the package inserts of new drugs.

Med Lett Drugs Ther. 1999 Jul 2; 41(1056):59-62
Reports of adverse interactions between drugs continue to accumulate. Recently, the FDA has expanded the recommendations on drug interactions found in the package inserts of new drugs.